Amgen To File Panitumumab In Second-Half 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
Application will seek approval for third-line treatment of colorectal cancer. Amgen says the anti-EGRF monoclonal antibody shows fewer adverse reactions than Bristol-Myers Squibb/Imclone's Erbitux.